Oculis (OCS) Expected to Announce Quarterly Earnings on Tuesday

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Oculis (NASDAQ:OCS - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 26th. Analysts expect Oculis to post earnings of ($0.53) per share and revenue of $0.14 million for the quarter.

Oculis Stock Performance

Shares of OCS stock opened at $18.06 on Tuesday. The stock's 50 day simple moving average is $18.52 and its 200 day simple moving average is $18.79. Oculis has a twelve month low of $10.79 and a twelve month high of $23.08. The company has a market capitalization of $788.50 million, a price-to-earnings ratio of -6.84 and a beta of 0.27.

Hedge Funds Weigh In On Oculis

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock worth $786,000 after acquiring an additional 878 shares in the last quarter. Marshall Wace LLP bought a new stake in Oculis during the 2nd quarter worth approximately $393,000. Finally, Geode Capital Management LLC raised its holdings in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after buying an additional 6,384 shares during the period. Institutional investors and hedge funds own 22.30% of the company's stock.

Wall Street Analyst Weigh In

Separately, Chardan Capital boosted their target price on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, May 9th.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.